Table 1 The summary of patient data
Variables | Number | % |
|---|---|---|
Gender | 95 | Â |
 Male | 47 | 49.5% |
 Fmale | 48 | 50.5% |
Age at diagnosis(years) | 95 | Â |
  < 45 | 47 | 49.5% |
  >  = 45 | 48 | 50.5% |
Mean | 9–79 |  |
 Hematology | 34 |  |
  Yes | 9 | 26.5% |
  No | 25 | 73.5% |
 Tumor size (mm) | 63 |  |
   < 45 | 31 | 49.2% |
   >  = 45 | 32 | 50.8% |
 T1-weighted | 74 |  |
  Iso-/Hypointense | 73 | 98.6% |
  Hyperintense | 1 | 1.4% |
 T2-weighted | 74 |  |
  Hypointense | 9 | 12.2% |
  Iso-/Hyperintense | 65 | 87.8% |
 Enhancement | 89 |  |
  Homogeneous | 55 | 61.8% |
  Heterogeneous | 19 | 21.3% |
  Yes | 15 | 16.9% |
 CT | 34 |  |
  Hyperintense | 17 | 50.0% |
  Isodense | 11 | 32.4% |
  Mixed density | 6 | 17.6% |
 Edema | 83 |  |
  Yes | 61 | 73.5% |
  No | 22 | 26.5% |
 EMA | 63 |  |
   +  | 62 | 98.4% |
  - | 1 | 1.6% |
 PR | 6 |  |
   +  | 3 | 50.0% |
  - | 3 | 50.0% |
 CD3 | 20 |  |
   +  | 19 | 95.0% |
  - | 1 | 5.0% |
 CD20 | 20 |  |
   +  | 19 | 95.0% |
  - | 1 | 5.0% |
 CD138 | 7 |  |
   +  | 7 | 100.0% |
  - | 0 | 0.0% |
 CD38 | 24 |  |
   +  | 23 | 95.8% |
  - | 1 | 4.3% |
 LCA | 46 |  |
   +  | 46 | 100.0% |
  - | 0 | 0.0% |
 Vimentin | 51 |  |
   +  | 50 | 98.0% |
  - | 1 | 2.0% |
 S-100 | 14 |  |
   +  | 11 | 78.6% |
  - | 3 | 27.3% |
 Ki67 + (%) | 16 |  |
   < 5 | 10 | 62.5% |
  5–10 | 4 | 25.0% |
   > 10 | 1 | 6.3% |
  NA | 1 | 6.3% |
 GFAP | 13 |  |
   +  | 3 | 23.1% |
  - | 10 | 76.9% |
 Surgery | 95 |  |
  GTR | 75 | 78.9% |
  STR | 20 | 26.7% |
 Radiotherapy | 80 |  |
  Yes | 10 | 12.5% |
  No | 70 | 87.5% |
 Recurrence | 93 |  |
  Yes | 7 | 7.5% |
  No | 86 | 92.5% |